Takeda Completes Acquisition Of IDM Pharma

Takeda has completed the acquisition of IDM Pharma for $2.64 per share in cash, through a short-form merger of Jade, a wholly-owned subsidiary of Takeda, into IDM. With the completion of the merger, IDM has become a wholly owned subsidiary of Takeda.

The acquisition also adds Mepact (mifamurtide), a therapy indicated for the treatment of osteosarcoma, to the Takeda oncology portfolio in Europe.

Erich Brunn, CEO of Takeda, said: With the closing of this acquisition, we look forward to launching Mepact in Europe. This novel therapy, the first treatment approved for osteosarcoma in more than 20 years, has the potential to benefit patients in an area where new treatments are urgently needed.”